Clene's NIH-Funded ALS Program For CNM-Au8 Expands Enrollment By 80%, Launches Data Collection In June
Portfolio Pulse from Benzinga Newsdesk
Clene's NIH-funded ALS program for CNM-Au8 has expanded enrollment by 80% and will begin data collection in June.
May 28, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clene's NIH-funded ALS program for CNM-Au8 has expanded enrollment by 80% and will begin data collection in June. This expansion could lead to significant advancements in ALS treatment and potentially boost investor confidence.
The expansion of the ALS program and the start of data collection are positive developments that could lead to advancements in treatment. This is likely to boost investor confidence and positively impact Clene's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100